REGN vs GILD
REGN and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | — | $181.41B |
| P/E (TTM) | 19.1 | 21.6 |
| P/B | — | 15.34 |
| P/S | — | 6.2x |
| Dividend yield | — | 2.21% |
| Revenue | $15.53B(TTM) | $30.46B(TTM) |
| Revenue growth (YoY) | 1.0% | 2.4% |
| Net income | $4.33B(TTM) | -$3.24B(TTM) |
| Earnings growth (YoY) | 2.1% | 1672.9% |
| EPS, diluted | $40.41(TTM) | $-2.65(TTM) |
| EBIT margin | 24.9% | 34.0% |
| ROE | 14.2% | 71.9% |
| ROIC | 9.4% | 26.7% |
| 1y total return | +35.0% | +32.9% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: REGN frente a GILD
| Métrica | REGN | GILD |
|---|---|---|
| Valor final | $21.4K | $25.5K |
| Retorno total | +113.7% | +154.7% |
| CAGR | +7.6% | +9.5% |
| Volatilidad | 32.1% | 25.6% |
| Sharpe | 0.26 | 0.32 |
| Sortino | 0.38 | 0.48 |
| Caída máxima | -59.7% | -30.5% |
Basado en 2600 días de negociación comunes, 2016-05-12 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)